OBJECTIVE:To systematically evaluate the effectiveness of Fuzheng Huayu preparation(扶正化瘀胶囊/片,FZHY)plus tenofovir disoproxil fumarate(TDF)on hepatitis B.METHODS:Numerous databases—PubM ed,Embase,Cochrane Librar...OBJECTIVE:To systematically evaluate the effectiveness of Fuzheng Huayu preparation(扶正化瘀胶囊/片,FZHY)plus tenofovir disoproxil fumarate(TDF)on hepatitis B.METHODS:Numerous databases—PubM ed,Embase,Cochrane Library,China National Knowledge Infrastructure Database,WanFang Database,China Science and Technology Journal Database,and China Biological Medicine Database—were searched to identify the randomized controlled trials published from the inception of the database to November 2021.Two researchers independently conducted literature screening,data extraction,and bias risk assessment.Rev Man 5.4 software was used for Meta-analysis.RESULTS:Eight studies involving 990 patients met the inclusion criteria in the current Meta-analysis.Levels of alanine transaminase,aspartate aminotransferase,total bilirubin,hyaluronic acid,typeⅢprocollagen,laminin,and type IV collagen after combination therapy were significantly lower than those after TDF therapy alone.However,albumin levels did not differ significantly between the two regimens.Subgroup analysis based on disease progression suggested that the combination therapy improved albumin levels in patients with chronic hepatitis B but not in patients with hepatitis B-related cirrhosis.Moreover,subgroup analysis based on treatment duration suggested that the albumin levels were increased and the typeⅢprocollagen levels were decreased with the>24-week combination therapy but not with the≤24-week combination therapy.CONCLUSIONS:A combination regimen of TDF and FZHY is more effective in treating hepatitis B than TDF alone.The combination therapy can effectively alleviate hepatic fibrosis and improve liver function.However,more standardized,highquality studies with larger sample sizes are warranted to validate the study results.展开更多
目的入院时空腹血糖水平升高与新型冠状病毒肺炎(COVID-19)患者病死率是否有关,目前研究结论存在矛盾,本研究采用Meta分析的方法探讨入院时空腹血糖水平升高与COVID-19患者病死率之间的关系。方法计算机检索PubMed、Embase、Web of Scie...目的入院时空腹血糖水平升高与新型冠状病毒肺炎(COVID-19)患者病死率是否有关,目前研究结论存在矛盾,本研究采用Meta分析的方法探讨入院时空腹血糖水平升高与COVID-19患者病死率之间的关系。方法计算机检索PubMed、Embase、Web of Science、Cochrane Library、中国生物医学文献服务系统、中国知网、万方数据知识服务平台、维普网等数据库,收集有关入院时空腹血糖水平升高与COVID-19患者病死率关系的相关文献(根据入院时空腹血糖水平是否升高将患者分为研究组和对照组)。检索时限为各数据库建库至2021-12-30。采用纽卡斯尔-渥太华量表(NOS)进行文献质量评价,采用RevMan 5.2进行Meta分析。结果共包括10篇文献中的5940例患者纳入研究。Meta分析结果显示,研究组COVID-19患者病死率高于对照组〔OR=5.31,95%CI(3.42,8.24),P<0.00001〕。根据空腹血糖水平升高诊断切点(分为≥7.0 mmol/L和≥7.7 mmol/L)及地域(分为来自中国和不是来自中国)进行亚组分析,不同空腹血糖水平升高诊断切点研究组COVID-19患者病死率高于对照组(P<0.05);来自中国的文献研究组COVID-19患者病死率高于对照组(P<0.05);不是来自中国的文献研究组与对照组COVID-19患者病死率比较,差异无统计学意义(P>0.05)。结论入院时空腹血糖水平升高与COVID-19患者病死率有关,但由于纳入文献均为回顾性研究,研究结果需谨慎对待,今后需要更大的样本量和高质量的前瞻性队列研究来验证这一结果。展开更多
基金Supported by the National Natural Science Foundation of China:the Molecular Mechanisms of Classical Prescription Sini Decoction plus Ginseng Soup to Rescue Acute Liver Failure:Regulating Hepatocyte Death Modes Mediated by PPARα/UCP2 Mitochondrial Uncoupling Pathway?(No.81973840)。
文摘OBJECTIVE:To systematically evaluate the effectiveness of Fuzheng Huayu preparation(扶正化瘀胶囊/片,FZHY)plus tenofovir disoproxil fumarate(TDF)on hepatitis B.METHODS:Numerous databases—PubM ed,Embase,Cochrane Library,China National Knowledge Infrastructure Database,WanFang Database,China Science and Technology Journal Database,and China Biological Medicine Database—were searched to identify the randomized controlled trials published from the inception of the database to November 2021.Two researchers independently conducted literature screening,data extraction,and bias risk assessment.Rev Man 5.4 software was used for Meta-analysis.RESULTS:Eight studies involving 990 patients met the inclusion criteria in the current Meta-analysis.Levels of alanine transaminase,aspartate aminotransferase,total bilirubin,hyaluronic acid,typeⅢprocollagen,laminin,and type IV collagen after combination therapy were significantly lower than those after TDF therapy alone.However,albumin levels did not differ significantly between the two regimens.Subgroup analysis based on disease progression suggested that the combination therapy improved albumin levels in patients with chronic hepatitis B but not in patients with hepatitis B-related cirrhosis.Moreover,subgroup analysis based on treatment duration suggested that the albumin levels were increased and the typeⅢprocollagen levels were decreased with the>24-week combination therapy but not with the≤24-week combination therapy.CONCLUSIONS:A combination regimen of TDF and FZHY is more effective in treating hepatitis B than TDF alone.The combination therapy can effectively alleviate hepatic fibrosis and improve liver function.However,more standardized,highquality studies with larger sample sizes are warranted to validate the study results.
